Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Authors:

Abstract
No abstract available
Funding Information
  • European and Developing Countries Clinical Trials Partnership (RIA2017MC-2005)
  • Medical Research Council (MC_UU_00004/03)
  • Medical Research Council (MC_UU_00004/04)
  • Université Catholique de Louvain
  • Janssen Pharmaceutica

This publication has 21 references indexed in Scilit: